Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
A director at Innate Pharma sold 10,000 shares at 5.500EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...
Update INNATE PHARMA BUY – TP EUR12 vs. 6.4 Monalizumab smiles again Innate Pharma’s equity story received a significant boost of confidence on the back of ESMO 2021, with the presentation of its ANKET platform, but most remarkably – monalizumab’s success in combination with AstraZeneca’s anti-PD-L1, durvalumab (Imfinzi), as a maintenance therapy for stage III NSCLC. Recall, Monalizumab is being developed in collaboration with AZ and the amendment of the expected milestone payment left investors doubting AZ’s confidence in this programme. At ESMO 2021, AZ presented impressive interim res...
Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021 MARSEILLE, France, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021: Total number of shares outstanding:79,294,402 ordinary shares 6,784 Preferred Shares 20...
NORTHAM PLATINUM HLDGS (ZA), a company active in the Platinum & Precious Metals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date October 19, 2021, the closing price was ZAR 227.00 and its potential was estimated at ZAR 246.58.
MASSMART (ZA), a company active in the Broadline Retailers industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date October 19, 2021, the closing price was ZAR 61.44 and its potential was estimated at ZAR 75.65.
The independent financial analyst theScreener just slightly lowered the general evaluation of AVI (ZA), active in the Food Products industry. The title has lost a star(s) at the fundamental level and now shows 3 out of 4 stars. Its exposure to market risk remains nonetheless the same and can be still described as defensive. theScreener slightly downgrades the general evaluation to Slightly Positive for the title on account of the lost star(s). As of the analysis date October 19, 2021, the closing price was ZAR 83.25 and its potential was estimated at ZAR 92.74.
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.